Author: Dev

Ventyx Biosciences doses first subject in a Phase 1 Trial of VTX-958, a selective allosteric TYK2 Inhibitor for Autoimmune Diseases

Ventyx Biosciences doses first subject in a Phase 1 Trial of VTX-958, a selective allosteric TYK2 Inhibitor for Autoimmune Diseases

Study to evaluate pharmacokinetics, safety and tolerability of VTX-958 as well as effects on biomarkers of TYK2-driven inflammatory signaling ENCINITAS, March 16, 2021 /PRNewswire/ —  Ventyx Biosciences, Inc. a clinical-stage biotechnology company developing oral, small molecule therapeutics for autoimmune disease, today announced the dosing of the first subject in a

Read More
ProterixBio announces commercial availability of a quantitative COVID-19 serology test validated for dried blood spots from a finger stick

ProterixBio announces commercial availability of a quantitative COVID-19 serology test validated for dried blood spots from a finger stick

Billerica, MA, February 11, 2020: ProterixBio, Inc. announced today commercial availability of a quantitative COVID-19 serology assay that has been validated for dried blood spots (DBS) from a finger stick. This is an update to the previously released SARS-CoV-2 (RBD) IgG Antibody test and is being offered as a testing

Read More
TigerConnect acquires Critical Alert

TigerConnect acquires Critical Alert

SANTA MONICA, California — January 6, 2021 — TigerConnect®, healthcare’s most advanced, reliable, and widely adopted care team collaboration solution, today announced the acquisition of Critical Alert®, a leading provider of enterprise-grade middleware for hospitals and health systems. Critical Alert’s product suite consists of a middleware suite of products as

Read More
ProterixBio Announces Commercial Availability of a Semi-Quantitative COVID-19 Antibody Test

ProterixBio Announces Commercial Availability of a Semi-Quantitative COVID-19 Antibody Test

Billerica, MA, September 29, 2020: ProterixBio, Inc. announced today commercial availability of the SARS-CoV-2 (RBD) IgG Antibody test, a semi-quantitative COVID-19 serology assay. It is being offered as a testing service through ProterixBio’s high-complexity clinical testing laboratory. Validation results demonstrated a Positive Percent Agreement (PPA) of 100% for samples acquired

Read More
Amarisoft and Dali Wireless Collaborate to Deliver Open RAN Based 4G and 5G Solutions

Amarisoft and Dali Wireless Collaborate to Deliver Open RAN Based 4G and 5G Solutions

Interoperability and co-marketing initiatives will bring new options for enterprises, and mobile network operators deploying in-building cellular solutions Menlo Park, California and Paris, France – February 11, 2020 – Dali Wireless, a global leader in wireless fronthaul innovation for virtual RAN, and Amarisoft, a pioneer in software centric 4G LTE

Read More
ProterixBio licenses COVID-19 serology test from Massachusetts General Hospital

ProterixBio licenses COVID-19 serology test from Massachusetts General Hospital

Billerica, MA, July 1, 2020: ProterixBio, Inc. today announced completing a licensing agreement with the Massachusetts General Hospital for a COVID-19 serology assay. The assay was developed and validated by researchers at the Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University which is a joint

Read More
Perceptimed Awarded NIH Development Grant

Perceptimed Awarded NIH Development Grant

PERCEPTIMED AWARDED $1.5M NIH DEVELOPMENT GRANT   MOUNTAIN VIEW, CA – PerceptiMed, Inc., was awarded a $1.5 million grant from the National Institutes of Health (NIH) to develop and test a secure, individual medication system for long-term care facilities.  Dr. Alan Jacobs, CEO and founder of PerceptiMed will serve as

Read More
Perceptimed Founder Jacobs To Speak At Bio2device Group Event

Perceptimed Founder Jacobs To Speak At Bio2device Group Event

PERCEPTIMED FOUNDER JACOBS TO SPEAK AT BIO2DEVICE GROUP EVENT MOUNTAIN VIEW, CA – April 25, 2014 – “Preventing Drug-Related Patient Injury and Death with Advanced, Cost-Effective Technology” is the topic Alan Jacobs, M.D., Ph.D., CEO and founder of PerceptiMed, will address at the Bio2Device lecture.  The lecture will take place

Read More
2019: A Look Back

2019: A Look Back

2019 was an exciting and busy year for us! As we take a look back at some of our milestones, we’d like to give a big thank you to all of our publishers. We’re looking forward to what’s in store in the coming year! We’re happy to report that 2019

Read More
For Digital Publishers, GTxcel’s New Content Hub is a Potential Game Changer

For Digital Publishers, GTxcel’s New Content Hub is a Potential Game Changer

Faced with a growing ecosystem of platforms and distribution channels, digital publishers rely on more sophisticated tools to effectively deliver content and maintain their brand cohesiveness. If you’re like most digital publishers, you probably maintain a network of content distribution channels. Your digital edition, branded website, blog, video channel, and

Read More
Not All Content is the Same

Not All Content is the Same

Introducing the document-centric table of contents. In documents such as whitepapers, research reports, and user manuals, content is typically organized differently than that of standard consumer publications. As an industry-leading publishing platform, our job is to ensure all readers have an exceptional user experience, regardless of the content they are

Read More
GTxcel launches custom analytics for 1,000+ unique customers, powered by Mixpanel

GTxcel launches custom analytics for 1,000+ unique customers, powered by Mixpanel

This article originally appeared in Mixpanel’s Customer Spotlight blog. GTxcel used Mixpanel to provide custom analytics to more than 1,000 media companies. In doing so, GTxcel customers get the data they need for mobile publishing and track metrics that matter most to drive readership. The goals GTxcel is a mobile-first, end-to-end

Read More